Header

UZH-Logo

Maintenance Infos

Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial


Wess, Gerhard; Kresken, Jan‐Gerd; Wendt, Ralph; Gaugele, Juliane; Killich, Markus; Keller, Lisa; Simak, Julia; Holler, Peter; Bauer, Alexander; Küchenhof, Helmut; Glaus, Tony (2020). Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. Journal of Veterinary Internal Medicine, 34(6):2232-2241.

Abstract

Background: Triple therapy (TT) consisting of furosemide, pimobendan, and anangiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for thetreatment of congestive heart failure (CHF) attributable to myxomatous mitral valvedisease (MMVD). However, the effect of adding an ACEI to the combination ofpimobendan and furosemide (dual therapy [DT]) so far has not been evaluatedprospectively.
Hypothesis: Triple therapy will extend survival time compared to DT in dogs withCHF secondary to MMVD.
Animals: Client-owned dogs presented with the first episode of CHF causedby MMVD.
Methods: Prospective, single-blinded, randomized multicenter study. One-hundredand fifty-eight dogs were recruited and prospectively randomized to receive eitherDT (furosemide and pimobendan) or TT (furosemide, pimobendan, and ramipril). Theprimary endpoint was a composite of cardiac death, euthanasia for heart failure, ortreatment failure.
Results: Seventy-seven dogs were randomized to receive DT and 79 to receiveTT. Two dogs were excluded from analysis. The primary endpoint was reached by136 dogs (87%; 66 dogs, DT; 70 dogs, TT). Median time to reach the primary end-point for all dogs in the study was 214 days (95% confidence interval [CI], 168-259 days). Median time to reach the primary endpoint was not significantly dif-ferent between the DT group (227 days; interquartile range [IQR], 103-636 days)compared with TT group (186 days; IQR, 72-453 days;P= .42).
Conclusions and Clinical Importance: Addition of the ACEI ramipril to pimobendanand furosemide did not have any beneficial effect on survival time in dogs with CHFsecondary to MMVD.

Abstract

Background: Triple therapy (TT) consisting of furosemide, pimobendan, and anangiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for thetreatment of congestive heart failure (CHF) attributable to myxomatous mitral valvedisease (MMVD). However, the effect of adding an ACEI to the combination ofpimobendan and furosemide (dual therapy [DT]) so far has not been evaluatedprospectively.
Hypothesis: Triple therapy will extend survival time compared to DT in dogs withCHF secondary to MMVD.
Animals: Client-owned dogs presented with the first episode of CHF causedby MMVD.
Methods: Prospective, single-blinded, randomized multicenter study. One-hundredand fifty-eight dogs were recruited and prospectively randomized to receive eitherDT (furosemide and pimobendan) or TT (furosemide, pimobendan, and ramipril). Theprimary endpoint was a composite of cardiac death, euthanasia for heart failure, ortreatment failure.
Results: Seventy-seven dogs were randomized to receive DT and 79 to receiveTT. Two dogs were excluded from analysis. The primary endpoint was reached by136 dogs (87%; 66 dogs, DT; 70 dogs, TT). Median time to reach the primary end-point for all dogs in the study was 214 days (95% confidence interval [CI], 168-259 days). Median time to reach the primary endpoint was not significantly dif-ferent between the DT group (227 days; interquartile range [IQR], 103-636 days)compared with TT group (186 days; IQR, 72-453 days;P= .42).
Conclusions and Clinical Importance: Addition of the ACEI ramipril to pimobendanand furosemide did not have any beneficial effect on survival time in dogs with CHFsecondary to MMVD.

Statistics

Citations

Dimensions.ai Metrics
1 citation in Web of Science®
1 citation in Scopus®
Google Scholar™

Altmetrics

Downloads

8 downloads since deposited on 24 Nov 2020
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Veterinary Clinic > Department of Small Animals
Dewey Decimal Classification:570 Life sciences; biology
630 Agriculture
Scopus Subject Areas:Health Sciences > General Veterinary
Uncontrolled Keywords:General Veterinary
Language:English
Date:1 November 2020
Deposited On:24 Nov 2020 16:28
Last Modified:28 Nov 2020 02:09
Publisher:Wiley Open Access
ISSN:0891-6640
OA Status:Gold
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1111/jvim.15863

Download

Gold Open Access

Download PDF  'Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial'.
Preview
Content: Published Version
Filetype: PDF
Size: 549kB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)